It is therefore necessary to identify inhibitory ligands, neutralizing antibodies or small molecule inhibitors of GPR133, or to engineer antibody-drug conjugates (ADCs) as therapeutics for GBM treatment. This evidence concerns the gene ADGRD1 and glioblastoma.